EMCDDA Home
  • EN

Figure GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15–34)

Part (ii) Countries with three or more surveys

 
 
YearBulgariaCzech RepublicDenmarkGermanyEstoniaIrelandGreeceSpainFrance ItalyLatviaHungaryNetherlandsPolandSlovakiaFinland SwedenUK (E&W)Norway
Related links:
19900.5
1991
1992
19930.2
19940.55.1
19951.71.90.7
19960.86.5
19971.11.7
19982.00.10.80.40.40.06.2
19991.40.11.5
20003.11.30.41.01.20.04.4
20012.30.11.40.83.1
20022.30.01.60.61.33.1
20032.22.90.81.60.42.41.93.0
20041.50.10.51.32.72.0
20050.92.20.20.60.72.6
20061.62.11.30.71.72.7
20071.00.81.91.21.8
20082.13.23.12.51.70.61.52.3
20090.31.91.41.80.8
20100.820.53.90.31.62.0
20111.40.81.10.61.4
Statistical bulletin 2008: Figure GPS-8 part (ii)
Statistical bulletin 2009: Figure GPS-8 part (ii)
Statistical bulletin 2010: Figure GPS-8 part (ii)
Statistical bulletin 2011: Figure GPS-8 part (ii)
Statistical bulletin 2012: Figure GPS-8 part (ii)
See also Table GPS-0
See also 'General notes for interpreting data' on the Explanatory notes and help page

Notes:

Sample sizes (respondents) for the 15 to 34 age group for each country and year are presented in Table GPS-8 part ii.

Data taken from national surveys available in each country. Figures and methodology for each survey can be consulted in Table GPS-8 part ii in the Statistical bulletin 2013.

For young adults, the EMCDDA uses the range 15 to 34 years (Denmark and UK from 16 years, Germany, Estonia (1998) and Hungary from 18 years). In France, the age range was 25 to 34 in 1992 and 18 to 39 in 1995.

The most recent general population survey reported by the Netherlands display a wide variation in results compared with 2005 which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.

The most recent general population survey reported by Italy display a wide variation in results compared with the previous surveys which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.

Sources:

Reitox national reports 2012, taken from population surveys, reports or scientific articles.

Year 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Bulgaria                               0.9   1.0 2.1      
Czech Republic                         2.3   1.5       3.2 0.3 0.8 1.4
Denmark         0.5           3.1         2.2     3.1   2  
Germany 0.5         1.7   1.1     1.3     2.2     1.6     1.9    
Estonia                 2.0         2.9         2.5      
Ireland                           0.8       0.8       0.8
Greece       0.2         0.1           0.1              
Spain           1.9   1.7   1.4   2.3   1.6     2.1   1.7 1.4   1.1
France            0.7       0.1 0.4   0.0     0.2         0.5  
Italy                       0.1   0.4   0.6     0.6      
Latvia                           2.4       1.9       0.6
Hungary                       1.4   1.9       1.2        
Netherlands                 0.8     0.8       0.7            
Poland                         1.6       1.3       3.9  
Slovakia             0.8   0.4   1.0   0.6   0.5   0.7       0.3  
Finland                  0.4   1.2   1.3   1.3   1.7       1.6  
Sweden                 0.0   0.0               1.5      
UK (E&W)         5.1   6.5   6.2   4.4 3.1 3.1 3.0 2.7 2.6 2.7 1.8 2.3 1.8 2.0 1.4
Norway                   1.5         2.0         0.8    

gpsfig8b

Demonstration Reference Type Y Axis X axis Label Width (%) Height (px) X plotline Y plotline Y min,max values series Markers
  szrfig1 column,column,line Quantity (kg)|Number of seizures$3                
  szrfig2 column,column,line Quantity (kg)|Number of seizures$3                
  gpsfig4a line %       500     0,30  
  gpsfig1 column %       500     0,25  
  gpsfig2 column,column,point Contiuation rates %|LTP all adults$3             0,  
  gpsfig18a distribution Estimated prevalence (%)             0  
  gpsfig18b distribution Estimated prevalence (%)             0  
  gpsfig20  column %       600      0,20  
  dlofig2 stackedBar %       600        
  dlofig3 line Index (2006 = 100)     68          
  dlofig3$ pie     1 135 701
reports
(2011)		 30          
  dlofig4  line Index (2006 = 100)     68          
  dlofig4$ pie      915 541 reports (2011) 30          
  dlofig5 line Index (2006 = 100)     68          
  dlofig5$ pie     179 418  reports (2011) 30          
  drdfig12a scatter Ratio between DRD in 2003 and 2000 Number of DRD in 2000         1    
  drdfig12b scatter Ratio between DRD in 2010/11 and 2003 Number of DRD in 2003         1    
  hsrfig2 stackedColumn Clients in substitution treatment                
  dlofig1 line Index (2006 = 100)             60,180  
  drdfig1 column Country and total number of DRD       600        
  drdfig2 column Proportion of DRD under the age of 25 (%)       600        
  drdfig3 line Mean age in years                
  drdfig4 line Mean age in years                
  drdfig5a line Index (1990 = 100)                
  drdfig5b line Index (1996 = 100)                
  drdfig6 line Index (1990 = 100 %)             80,160  
  drdfig7a column Mortality rate per million                
  drdfig7b column,point Rate per million                
  drdfig8 line Index (1985 = 100 %)             50,650  
  drdfig9a line %             0,70  
  drdfig9b line %                
  drdfig9c line %                
  drdfig10 column Mean age in years       500        
  drdfig11a line Index             0,300  
  drdfig11b line Index                
  drdfig11c line Index                
  drdfig13a line Number of cases                
  drdfig13b line Number of cases                
  eyefig1a line                  
  eyefig1b line                  
  eyefig1c line               0,  
  eyefig1d line %     45 800        
  eyefig1d$ line %     45 800        
  gpsfig3 column %       500        
  gpsfig4b line %                
  gpsfig5 column %                
  gpsfig6 column %                
  gpsfig7 column %                
  gpsfig8a line %             0,  
  gpsfig8b line %             0,  
  gpsfig9a column %                
  gpsfig9b column %                
  gpsfig10 line %                
  gpsfig11 column,column,point Continuation rates (%)| LTP All adults$3                
  gpsfig12a line %             0,  
  gpsfig12b line %             0,  
  gpsfig13 column,column,point %                
  gpsfig14a line %             0,  
  gpsfig14b line %             0,  
  gpsfig15 column %                
  gpsfig16

column,column,point

 Continuation rates (%)|LTP All adults$3             0,  
  gpsfig17 column %                
  gpsfig21a line %             0,  
  gpsfig21b line %             0,  
  gpsfig22 column,column,point Continuation rates (%)| LTP All adults$3                
  gpsfig23a line %                
  gpsfig23b line %                
  gpsfig23c line %                
  gpsfig23d line %             0,  
  gpsfig23e line %             0,  
  hsrfig4 pie     % of prison population in OST 30          
  inffig1a line New AIDS cases per million population       700     0,  
  inffig1b line New AIDS cases per million population       700     0,  
  inffig2a line Cases per million population             0,  
 

inffig2b

line

 Cases per million population             0,  
  inffig2c line Cases per million population                
  inffig2d line Cases per million population                
  inffig3a distribution %             0, National;Subnational|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
  inffig3b distribution %             0, National;Subnational|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
  inffig3c distribution %             0, National;Subnational|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
  inffig6a distribution %             0, National;Subnational|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
  inffig6b distribution %             0, National;Subnational|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
  inffig6c distribution %             0, National;Subnational|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
  inffig9a distribution %             0, National;Subnational|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
  inffig9b distribution %             0, National;Subnational|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
  pppfig1 line Index (2005 = 100)                
  pppfig2 line Index (2005 = 100)                
  tdifig1a line %                
  tdifig1b line                  
  tdifig2a pie       30          
  tdifig2b pie       50          
  tdifig3a line %                
  tdifig3b line                  
  tdifig7 line %     60       0,  
  tdifig7$ stackedColumn Numbers     38        0,50000  
  hsrfig1b stackedColumn %                
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
Distirbuted points with specific markers and colours inffig6a distribution %               National;Subnational|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
                       

 

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Tuesday, 30 April 2013